Physician profile
Subu Dubey
NPI 1891170684
$3,497.17
in general payments reported to CMS, 2019-2025
13 companies · $717 in 2025
The $717 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $395 · 2021: $676 · 2022: $279 · 2023: $704 · 2024: $602 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,038.56 | 2021-2025 | Caplyta |
| Braeburn INC. | $598.00 | 2023-2025 | Brixadi |
| Abbvie INC. | $454.46 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $371.91 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Corium, LLC | $324.58 | 2022-2023 | Azstarys |
| Alkermes, INC. | $216.24 | 2020-2023 | Aristada, Lybalvi |
| Allergan, INC. | $181.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $108.04 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $70.37 | 2021-2022 | |
| Indivior INC. | $64.20 | 2020-2021 | |
| Lilly USA, LLC | $27.79 | 2021 | |
| Axsome Therapeutics, INC. | $24.76 | 2022 | |
| Neurocrine Biosciences, INC. | $17.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subu Dubey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.